Pacific Biosciences Of California (PACB) Liabilities and Shareholders Equity (2010 - 2026)

Pacific Biosciences Of California has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $751.8 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 8.92% year-over-year to $751.8 million in Q2 2026; TTM through Jun 2026 was $3.1 billion, a 29.01% decrease from a year earlier, with the FY2025 full-year figure at $784.1 million, down 37.79% from the prior year.
• Liabilities and Shareholders Equity was $751.8 million for Q2 2026 at Pacific Biosciences Of California, down from $782.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.9 billion in Q1 2022, with the low at $751.8 million in Q2 2026.
• Average Liabilities and Shareholders Equity over 5 years is $1.4 billion, with a median of $1.6 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 56688.92% in 2022, then tumbled 48.45% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then decreased by 1.19% to $1.7 billion in 2023, then retreated by 27.81% to $1.3 billion in 2024, then sank by 37.79% to $784.1 million in 2025, then retreated by 4.11% to $751.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $751.8 million (Q2 2026), $782.4 million (Q1 2026), and $784.1 million (Q4 2025), per Business Quant data.